Hepatitis News and Research

RSS

Infect, replicate, and rapidly mutate: Computational virus modeling study

A new bioRxiv* preprint study led by Barbara A Jones of IBM Research-Almaden in San Jose, California, used computational modeling to investigate how viruses rapidly mutate as well as how they respond or adapt to different host conditions. They observed a range of behaviors from glassy dynamics, bimodal quasispecies distributions, and periodic steady states.

22 Dec 2021

ACTG announces the launch of clinical trial to evaluate new CMV vaccine in adults

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5355, a clinical trial studying a new cytomegalovirus (CMV) vaccine in adults with both HIV and CMV.

16 Dec 2021

Exploring the possibility of developing a plant-based oral vaccine against COVID-19

New research optimizes methods for the in-planta expression of the recombinant protein corresponding to the Receptor Binding Domain (RBD) subunit of the surface-exposed Spike glycoprotein of SARS-CoV-2.

15 Dec 2021

Risk of Guillain-Barré syndrome decreases after COVID-19 vaccination

A new study suggests that low GBS incidence in vaccinated patients compared to non-vaccinated people should encourage the active propagation of vaccination against SARS-CoV-2.

15 Dec 2021

Bioinformatics pipeline can be used to quickly identify SARS-CoV-2 therapeutics

In a new study, researchers developed a bioinformatics pipeline that uses RNA sequencing data to identify altered genes and signaling pathways affected by viral infection.

13 Dec 2021

New insights about COVID-19 vaccination rates among people living with HIV

The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that insights around COVID-19 vaccination rates among people living with HV have been published in the Journal of Infectious Diseases.

10 Dec 2021

Analysis finds substantially more mutations in the omicron SARS-CoV-2 variant

A University of Florida Health researcher has successfully analyzed the many mutations in the omicron variant of the SARS-CoV-2 virus, a crucial step in better understanding the variant's potential threat and ways to combat it.

9 Dec 2021

Characterization of the baseline SARS-CoV-2 S-reactive B cell repertoire

Researchers from the University Of Amsterdam have identified several oddities in unvaccinated individuals' antibody response to the spike protein.

8 Dec 2021

Interactions between RNA viruses and human RNA-binding proteins

During the virus's attempt to use the host cell to replicate, host proteins interact heavily with the viral genome. Researchers have been investigating these interactions.

8 Dec 2021

Safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine

Researchers have presented the results of phase 1 and phase 2 clinical trials of a SARS-CoV-2 recombinant spike protein vaccine (Abdala).

6 Dec 2021

Is it time to change the definition of ‘fully vaccinated’?

As more indoor venues require proof of vaccination for entrance and with winter — as well as omicron, a new covid variant — looming, scientists and public health officials are debating when it will be time to change the definition of "fully vaccinated" to include a booster shot.

3 Dec 2021

Plant-derived virus-like particle vaccines against SARS-CoV-2

In a review published in Biotechnology Letters, the authors discuss plant-derived VLP-based vaccines.

1 Dec 2021

Prevalence of menstrual changes following vaccination against COVID-19

A new study investigates the relationship between COVID-19 vaccination and menstrual cycle disturbances.

26 Nov 2021

Direct-acting antivirals for HCV-related hepatocellular carcinoma reduces the risk of tumor progression

In a new cohort study of patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC), a disease with a high recurrence rate, researchers at the Osaka City University Graduate School of Medicine reported that after receiving cancer treatment, the oral administration of direct-acting antivirals (DAA) reduces the risk of tumor progression following recurrence of the liver disease.

25 Nov 2021